CO2021016606A2 - Métodos para administrar un anticuerpo anti-cd38 para tratar el mieloma múltiple - Google Patents
Métodos para administrar un anticuerpo anti-cd38 para tratar el mieloma múltipleInfo
- Publication number
- CO2021016606A2 CO2021016606A2 CONC2021/0016606A CO2021016606A CO2021016606A2 CO 2021016606 A2 CO2021016606 A2 CO 2021016606A2 CO 2021016606 A CO2021016606 A CO 2021016606A CO 2021016606 A2 CO2021016606 A2 CO 2021016606A2
- Authority
- CO
- Colombia
- Prior art keywords
- antibody
- administering
- methods
- multiple myeloma
- treat multiple
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/804—Blood cells [leukemia, lymphoma]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Se proporcionan métodos para tratar a un individuo humano que tiene mieloma múltiple que comprenden administrar al individuo 10 mg/kg de isatuximab mediante infusión intravenosa, en donde el volumen de cada infusión de 10 mg/kg de isatuximab es 250 ml. También se proporcionan métodos para tratar a un individuo humano que tiene mieloma múltiple que comprenden administrar un anticuerpo anti-CD38 en ciclos de 28 días, en donde el anticuerpo anti-CD38 se administra en los Días 1, 8, 15, y 22 de un primer ciclo de 28 días, en donde el anticuerpo frente a CD38 se administra en los Días 1 y 15 de cada ciclo de 28 días después del primer ciclo de 28 días; y en donde el anticuerpo anti-CD38 se administra a una dosis de 10 mg/kg o 20 mg/kg.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962847825P | 2019-05-14 | 2019-05-14 | |
| US201962860739P | 2019-06-12 | 2019-06-12 | |
| US201962899088P | 2019-09-11 | 2019-09-11 | |
| EP20305223 | 2020-03-03 | ||
| PCT/US2020/032754 WO2020232173A1 (en) | 2019-05-14 | 2020-05-13 | Methods of administering anti-cd38 antibody to treat multiple myeloma |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2021016606A2 true CO2021016606A2 (es) | 2022-04-29 |
Family
ID=71094805
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2021/0016606A CO2021016606A2 (es) | 2019-05-14 | 2021-12-07 | Métodos para administrar un anticuerpo anti-cd38 para tratar el mieloma múltiple |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20210171650A1 (es) |
| EP (1) | EP3969004A1 (es) |
| JP (1) | JP2022532356A (es) |
| KR (1) | KR20220008305A (es) |
| CN (1) | CN114080233A (es) |
| AU (1) | AU2020274169A1 (es) |
| BR (1) | BR112021022503A2 (es) |
| CA (1) | CA3140034A1 (es) |
| CO (1) | CO2021016606A2 (es) |
| IL (1) | IL287832A (es) |
| MA (1) | MA55967A (es) |
| MX (1) | MX2021013910A (es) |
| SG (1) | SG11202112513YA (es) |
| TW (1) | TW202108624A (es) |
| WO (1) | WO2020232173A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3197381A1 (en) * | 2020-11-03 | 2022-05-12 | Sanofi-Aventis U.S. Llc | Use of isatuximab for the treatment of multiple myeloma |
| AU2022253256A1 (en) * | 2021-04-08 | 2023-11-16 | Artiva Biotherapeutics, Inc. | Treatment of cancer with nk cells and a cd38-targeted antibody |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1914242A1 (en) | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
| US10342869B2 (en) * | 2012-12-07 | 2019-07-09 | The Regents Of The University Of California | Compositions comprising anti-CD38 antibodies and lenalidomide |
| EP3917961A1 (en) * | 2019-01-28 | 2021-12-08 | Sanofi | Methods of treating multiple myeloma |
-
2020
- 2020-05-13 AU AU2020274169A patent/AU2020274169A1/en active Pending
- 2020-05-13 MA MA055967A patent/MA55967A/fr unknown
- 2020-05-13 CN CN202080049892.8A patent/CN114080233A/zh active Pending
- 2020-05-13 EP EP20733081.2A patent/EP3969004A1/en active Pending
- 2020-05-13 BR BR112021022503A patent/BR112021022503A2/pt unknown
- 2020-05-13 US US15/931,466 patent/US20210171650A1/en active Pending
- 2020-05-13 KR KR1020217040398A patent/KR20220008305A/ko unknown
- 2020-05-13 WO PCT/US2020/032754 patent/WO2020232173A1/en active Application Filing
- 2020-05-13 MX MX2021013910A patent/MX2021013910A/es unknown
- 2020-05-13 CA CA3140034A patent/CA3140034A1/en active Pending
- 2020-05-13 SG SG11202112513YA patent/SG11202112513YA/en unknown
- 2020-05-13 JP JP2021567963A patent/JP2022532356A/ja active Pending
- 2020-05-14 TW TW109116104A patent/TW202108624A/zh unknown
-
2021
- 2021-11-04 IL IL287832A patent/IL287832A/en unknown
- 2021-12-07 CO CONC2021/0016606A patent/CO2021016606A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW202108624A (zh) | 2021-03-01 |
| MA55967A (fr) | 2022-03-23 |
| EP3969004A1 (en) | 2022-03-23 |
| AU2020274169A1 (en) | 2022-01-20 |
| CA3140034A1 (en) | 2020-11-19 |
| CN114080233A (zh) | 2022-02-22 |
| MX2021013910A (es) | 2022-03-11 |
| IL287832A (en) | 2022-01-01 |
| KR20220008305A (ko) | 2022-01-20 |
| WO2020232173A1 (en) | 2020-11-19 |
| SG11202112513YA (en) | 2021-12-30 |
| US20210171650A1 (en) | 2021-06-10 |
| BR112021022503A2 (pt) | 2021-12-28 |
| JP2022532356A (ja) | 2022-07-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2021016606A2 (es) | Métodos para administrar un anticuerpo anti-cd38 para tratar el mieloma múltiple | |
| PE20190205A1 (es) | Uso de inhibidores de miostatina y terapias de combinacion | |
| AR105027A1 (es) | Métodos de tratamiento del cáncer de mama localmente avanzado o metastásico usando antagonistas del eje de pd-1 y taxanos | |
| PH12020500555A1 (en) | Esketamine for the treatment of depression | |
| AR104771A1 (es) | Inhalador de polvo seco | |
| JP2012131811A5 (es) | ||
| MD3883606T3 (ro) | Metodă sigură și eficientă de tratament al colitei ulcerative cu anticorpi anti-IL12/IL23 | |
| ECSP22049008A (es) | M?todos de tratamiento del c?ncer de pulm?n de c?lulas peque?as con formulaciones de lurbinectedina | |
| CL2021001389A1 (es) | Formulaciones en cápsula | |
| MX2023007826A (es) | Metodos que comprenden una dosificacion intermitente fija de cediranib. | |
| CO2020008561A2 (es) | Dosificación subcutánea de anticuerpos anti-cd38 | |
| AR120399A1 (es) | Un método de tratamiento de un cáncer positivo para dll3 | |
| AR111491A1 (es) | Métodos para tratar enfermedades pediátricas | |
| AR102903A1 (es) | Inhalador de polvo seco | |
| PE20180023A1 (es) | Metodos para el tratamiento de mujeres con trastorno del deseo sexual hipoactivo (hsdd) con el tratamiento de combinacion de bupropion y trazodona | |
| AR125403A1 (es) | Métodos para el tratamiento de cánceres | |
| AR115563A1 (es) | Suministro de microdistrofina específica de músculo mediante vectores de virus adenoasociados para tratar la distrofia muscular | |
| CO2023017669A2 (es) | Terapia combinada anti-vhc ventajosa | |
| AR114012A1 (es) | Método para proporcionar terapia de celiprolol a un paciente | |
| AR126183A1 (es) | Terapia de combinación anti-hcv ventajosa | |
| UA116600U (uk) | Спосіб лікування гострого ішемічного інсульту | |
| PL431290A1 (pl) | Bezpieczna metoda podawania substancji ślimakom w formie iniekcji dożylnych | |
| JP1745174S (ja) | ズボン | |
| JP1745173S (ja) | ズボン | |
| AR121518A1 (es) | Métodos para usar rebastinib en el tratamiento de trastornos |